Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 3,278 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Not listed Phase 1 Interventional

PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies

NCT01522989
View directory record Official record
Conditions
Advanced Solid Tumor Malignancies
Interventions
PD-0332991, 5-FU, Oxaliplatin
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 30, 2026, 6:16 AM EDT
Completed No phase listed Observational

The Effect of Dexmedetomidine of the Immune System

NCT01692210
View directory record Official record
Conditions
Breast Cancer
Interventions
Dexmedetomidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors

NCT03042910
View directory record Official record
Conditions
Solid Tumor
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
19
States / cities
Bakersfield, California • Burbank, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 6:16 AM EDT
Completed No phase listed Observational

A Study to Learn About the Dangers Linked to Myelosuppression (Decreased Bone Marrow Function) in Breast Cancer Patients Treated With the Study Medicine Palbociclib (Pal Bow Sai Klib)

NCT05709158
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
4,184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 6:16 AM EDT
Active, not recruiting Phase 2 Interventional

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

NCT04841148
View directory record Official record
Conditions
Breast Cancer
Interventions
HCQ, Avelumab, Palbociclib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 6:16 AM EDT
Active, not recruiting Phase 4 Interventional

A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.

NCT05295290
View directory record Official record
Conditions
Myocarditis
Interventions
Cardiac Imaging
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
0 Years to 20 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
18
States / cities
Los Angeles, California • Madera, California • Hartford, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 30, 2026, 6:16 AM EDT
Withdrawn Not applicable Interventional

Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis

NCT02720874
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Rheumatoid arthritis educational booklet, Multidisciplinary rheumatologic care, Nurse education and monthly calls, Monthly healthcare coordinator calls, Technology-based symptom monitoring and reporting
Behavioral
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 4 Interventional

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

NCT00230789
View directory record Official record
Conditions
Urinary Incontinence
Interventions
Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
Drug · Behavioral
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
51
States / cities
Phoenix, Arizona • Sun Lakes, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease

NCT00376168
View directory record Official record
Conditions
Gaucher Disease
Interventions
Plant cell expressed recombinant glucocerebrosidase (prGCD)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Coral Springs, Florida • Decatur, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2018 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

NCT02364596
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
SA4Ag vaccine, Blood sample
Biological · Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Hollywood, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 30, 2026, 6:16 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

NCT07765888
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tilrekimig, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery

NCT00927888
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Bupivacaine Block, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Exercise to Treat Depression in Individuals With Coronary Heart Disease

NCT00302068
View directory record Official record
Conditions
Depression, Heart Diseases
Interventions
Supervised Aerobic Exercise, Sertraline, Placebo Pill.
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
35 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 30, 2026, 6:16 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults

NCT07226882
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 44 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
6
States / cities
Warren Township, New Jersey • Cortland, New York • Horseheads, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 6:16 AM EDT
Recruiting Phase 3 Interventional

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

NCT06650579
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Bicalutamide, Biospecimen Collection, Computed Tomography Angiography, Leuprolide, Prednisone, Radiation Therapy, Relugolix
Drug · Procedure · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 2 Interventional Results available

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

NCT00640146
View directory record Official record
Conditions
Opioid-induced Constipation
Interventions
Methylnaltrexone bromide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

NCT06137742
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PF-07868489, Placebo for PF-07868489
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
16
States / cities
Anaheim, California • Costa Mesa, California • Orange, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 3 Interventional Results available

Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature

NCT00396097
View directory record Official record
Conditions
Idiopathic Short Stature
Interventions
Genotropin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Years to 10 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
43
States / cities
Little Rock, Alaska • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2016 · Synced Oct 30, 2026, 6:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder

NCT02216097
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
PF-04457845, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

NCT01435382
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
7
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 4 Interventional Results available

A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects

NCT00807846
View directory record Official record
Conditions
Arthritis, Juvenile Rheumatoid
Interventions
Celecoxib, Naproxen
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
2 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 30, 2026, 6:16 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy

NCT01087203
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Tanezumab, placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
48
States / cities
Mobile, Alabama • Goodyear, Arizona • Litchfield Park, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 30, 2026, 6:16 AM EDT
Completed Phase 1 Interventional

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

NCT03665454
View directory record Official record
Conditions
Parkinson Disease
Interventions
PF-06412562, Standard of Care Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 30, 2026, 6:16 AM EDT